一、个人简介
博士，中国疾控预防控制中心性病艾滋病预防控制中心研究员，博士生导师，传染病预防控制国家重点实验室PI，感染性疾病诊治协同创新中心PI, 性艾中心病免室生物学课题组负责人。国家自然科学基金同行评议人；卫生部生物安全三级实验室活动能力评审专家；科技部国际科技合作计划评价专家；教育部学位中心学位与研究生教育专家;北京市科技成果和评审专家；中华实验和临床病毒学杂志编委委员 。2001—2005分别在法国科学院巴黎第六大学和美国纽约血液中心从事HIV的研究。回国后先后承担并参与国家自然科学基金5项、973项目、“十一五”重大专项十五攻关项目、863项目和美国NIH支助的CIPRA 和HPTN058项目以及盖茨基金资助的CA-VIMC项目。近年来在国内外杂志累计发表文章80篇，其中分别在
二、主要研究方向
1. HIV生物学和致病机制研究；2. HIV的耐药机制和新药物研究
三、代表性科研项目
1. 国家自然科学基金国际(地区)合作与交流项目，81561128006，
通过多价双特异性抗体介导的ADCC清除HIV潜伏感染细胞的研究，2016/01-2018/12，200万元，在研，主持
2. 国家自然科学基金国际(地区)合作与交流项目，8126112038，靶向衣壳蛋白的抗病毒抑制剂对中国重组HIV流行株的敏感性和耐药性研究，2013/01-2013/12，30万元，已结题，主持
3. 国家自然科学基金面上项目，81172733，HIV准种变异程度对3TC耐药性产生的影响研究，2012/01-2015/12，55万元，已结题，主持
4. 国家自然科学基金面上项目，30872232，我国HIV-1流行株CRF07_B/C的pol区新突变位点对逆转录酶抑制剂的耐药机制研究，2009/01-2011/12，33万元，已结题，主持
四、代表性论文、成果（2012年以来）
1. Kong D, Wang Y, Wang C, Liang S, Feng Y, Ruan Y, Shao Y, Ma L. Characterization of a New HIV-1 CRF01_AE/CRF07_BC Recombinant virus in Guangxi, China. AIDS Res Hum Retroviruses. 2017 Jun 6. doi: 10.1089/AID.2017.0101.
(通讯作者）
2. Wang Y, Kong D, Xu W, Li F, Liang S, Feng Y, Zhang F, Shao Y, Ma L. Identification of a Novel HIV Type 1 CRF01_AE/B'/C
Recombinant Isolate in Sichuan, China. AIDS Res Hum Retroviruses. 2017 Jun;33(6):621-628. (通讯作者）
3. Li F, Feng Y, Ni N, Hu J, Ruan Y, Shao Y, Ma L. Five Near Full-Length Hepatitis C Virus Sequences Were Identified from HIV Coinfected Injection Drug Users of China. AIDS Res Hum Retroviruses.
2017 May;33(5):496-499. (通讯作者）
4. Sun Y, Xu W, Fan N, Sun X, Ning X, Ma L, Liu J, Wang X. Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase. Bioorg Med Chem. 2017 Feb 1;25(3):1076-1084. (通讯作者）
5. Wang Y, Wei H, Xu W, Yin Q, Feng Y, Liang S, Shao Y, Ma L. Identification of a Novel CRF01_AE/CRF07_BC Recombinant Form in
Men Who Have Sex with Men in Sichuan, China. AIDS Res Hum Retroviruses. 2016 Jul 32(7): 718-21.
6. Wang Y, Ma L, Xu W, Li F, Liang S, Feng Y, Shao Y, Zhang F. Near Full-Length Genome Identification of a Novel HIV-1 Unique (B/C) Recombinant Isolate in Sichuan, China. AIDS Res Hum Retroviruses. 2016 Aug 3.
7. Cheng S, Wang Y, Zhang Z, Lv X, Gao GF, Shao Y, Ma L, Li X. Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties. Eur J Med Chem. 2016 Oct 4; 121: 232-7.
8. Yin Q, Li Z, Zhao H, Pan D, Wang Y, Xu W, Xing H, Feng Y, Jiang S, Shao Y, Ma L. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase. Biomedical & Environmental Sciences, 2016 Apr 29(4): 239-247
9. Jiao Y, Zhang X, Wang C, Li L, Liu J, Bar KJ, Wei H, Hu Y, Huang P, Zeng Z, Jiang S, Du J, Shao Y, Metzger D, Li S, Ma L.
Hepatitis C Virus Subtype and Evolution Characteristic Among Drug Users, Men Who Have Sex With Men, and the General Population
in Beijing, China. Medicine (Baltimore). 2016 Feb; 95(6): e2688.
10. Xu W, Zhao J, Sun J, Yin Q, Wang Y, Jiao Y, Liu J, Jiang S, Shao Y, Wang X, Ma L. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes. Antimicrob Agents Chemother. 2015 Aug 59(8): 4882-8.
11. Li Z, Huang Y, Ouyang Y, Jiao Y, Xing H, Liao L, Jiang S, Shao Y, Ma L*, CorMut: an R/Bioconductor package for
computingcorrelated mutations based on selection pressure. Bioinformatics. 2014. IF: 5.323
12. Huang Y, Li Z, Xing H, Jiao Y, Ouyang Y, Liao L, Jiang S, R Armstrong, Shao Y, Ma L*, Identification of the Critical
Sites of NNRTI-Resistance in Reverse Transcriptase of HIV-1 CRF_BC Strains. PLos One 2014; 9(4): e93804. IF: 3.73
13. Yin Q, Shao Y, Ma L*, HIV cure and HIV reservoirs. Biomed Environ Sci. 2014 Jun;27(6):478-80
14. Li Z, Huang Y, Ouyang Y, Xing H, Liao L, Jiang S, Shao Y, Ma L*，Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy，Journal of Antimicrobial Chemotherapy 2013; 8(11): 2521-2524. IF: 5.338
15. Li A, Ouyang Y, Wang Z, Cao Y, Liu X, Ran L, Li C, Li L, Zhang L, Qiao K, Xu W, Huang Y, Zhang Z, Tian C, Liu Z, Jiang S,
Shao Y, Du Y, Ma L*, Wang X*, Liu J*，Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains, Journal of Medicinal Chemistry 2013; 56(9): 3593-3608. IF: 5.614
16. Ouyang Y, Sun J, Huang Y, Lu L, Xu W, Hu X, Hong K, Jiang S, Shao Y, Ma L*. Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. Virol J 2013;10:10.
17. Wang X, Zhang J, Huang Y, Wang R, Zhang L, Qiao K, Li L, Liu C, Ouyang Y, Xu W, Zhang Z, Zhang L, Shao Y, Jiang S, Ma L*,
Liu J. Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. J Med Chem 2012;55:2242-50.
2. 既非第一作者又非通讯作者论文
1、 Li F, Ma L, Feng Y, Hu J, Ni N, Ruan Y, Shao Y. Generation and Characterization of HIV-1 Transmitted and Founder Virus Consensus Sequence from Intravenous Drug Users in Xinjiang, China. AIDS Res Hum Retroviruses.
2017 Jun;33(6):610-613.
2、Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, Liu Y, Wang X, Li H, Lai W, He Y, Yao A, Ma L, Shao Y, Zhang B, Wang C, Chen H,
Deng H. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo. Mol Ther. 2017 May 17. pii: S1525-0016(17)30213-7.
3、Hu X, Hu Y, Zhao C, Gao H, Greene KM, Ren L, Ma L, Ruan Y, Sarzotti-Kelsoe M, Montefiori DC, Hong K, Shao Y. Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users na？ve to antiretroviral therapy. Sci Rep. 2017 Apr 7;7:46308.
4、Wang Z, Zhang J, Li F, Ji X, Liao L, Ma L, Xing H, Feng Y, Li D, Shao Y. Drug resistance-related mutations T369V/I in the connection subdomain of HIV-1 reverse transcriptase severely impair viral fitness. Virus Res. 2017 Apr 2;233:8-16.
5、Wang Y ， ，Zhang F ，Ma L Near Full-Length Genome Identification of a Novel HIV-1 Unique (B/C) Recombinant Isolate in Sichuan, China.，AIDS Research and Human Retroviruses，2016.8.01
6、 .Cheng S，Chang X，Wang Y，Gao GF，Shao Y，Ma L，Li X.，Glycosylated
Enfuvirtide: A Long-Lasting Glycopeptide with Potent Anti-HIV Activity.，J Med Chem.，2015.2.12，58（3）：1372~1379
7、Zhang Y，Zhang L，Sun J，Liu Y，Ma X，Cui S，Ma L，Xi JJ，Jiang X ，
(*) Point-of-care multiplexed assays of nucleic acids using microcapillary-based loop-mediated isothermal amplification.，Anal Chem，2014.7.15，86（14）：7057~7 062
8、 .Zhang L，Ma L，Wang Z，Wang Y，Zhang J，Wang H，Shao Y*，Alterations
in HIV-1 gp120 V3 Region are Necessary but not Sufficient for Coreceptor
Switching in CRF07_BC in China，PLOS ONE，2014.3.27，9（3）
9、Jackson JB，Wei L，Liping F，Aramrattana A，Celentano DD，Walshe
L，Xing Y，Richardson P，Jun M，Beauchamp G，Donnell D，Ruan Y7，Ma L，Metzger D，Shao Y ，Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in china and Thailand.，Hepat Res Treat27，2014.3.01，0（0）
10、Xu L，Liu Y，Chen Z，Li W，Liu Y，Wang L，Ma L，Shao Y，Zhao Y，Chen C MorphologicallyVirus-Like Fullerenol Nanoparticles Act as the
Dual-Functional Nanoadjuvant forHIV-1 Vaccine，Adv Mater，2013.11.6，25（41）：5928~5936
11、Li, Li，Ma, Liying，Wang, Xiaowei ，Liu, Junyi，New Efficient and
Flexible Synthetic Route to Emivirine and Its Analogs，JOURNAL OF HETEROCYCLIC CHEMISTRY，2013.1.01，50（1）：164~168
12、Zhang, Yi，Wang, Xuwei，Song, Lusheng，Xu, Chuanlai，Ma, Liying，Li,Zhanhua，Xi, Jianzhong ，Jiang, Xingyu，Matrix-localization for fast analysis of arrayed microfluidic immunoassays，ANALYTICAL METHODS，2012.10.01，4（10）：3466~3470
13、 Hu, Xintao，Hong, Kunxue，Zhao, Chunhong，Zheng, Yang，Ma, Liying，Ruan, Yuhua，Gao, Hongmei，Greene, Kelli，Sarzotti-Kelsoe, Marcella，Montefiori,David C.，Shao, Yiming ，Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B '-infected former plasma donors from China naive to antiretroviral therapy，JOURNAL OF GENERAL VIROLOGY，2012.10.01，93：2267~2278
二、授权发明专利
(1) 李学兵，程水红，马丽英，邵一鸣，一种糖基化多肽及其制备方法和其应用，20 15.6.24，其他国家，CN201310704596.9
(2) 李学兵，程水红，马丽英，邵一鸣，一种PEG化多肽及其制备方法和其应用，201 5.6.24，其他国家，CN201310706149.7
(3) 王孝伟，张建芳，刘俊义，马丽英，新型HEPT类HIV-1逆转录酶抑制剂的制备及其应用，2014.9.24，中国，ZL201010208308.7
三、获得学术奖励
(1) 马丽英（2/15），我国HIV耐药检测技术平台的建立及推广应用，中华预防医学会，2013中华预防医学科技奖，二等奖，2015.1.27
(2) 马丽英（2/15），我国HIV耐药检测技术平台的建立及推广应用，北京市人民政府，北京市科学技术奖，三等奖，2014.3.25
扫码关注疾控学子